炎性肌病相关间质性肺病1年肺功能变化的预后意义
该回顾性单中心队列纳入149例炎性肌病相关间质性肺病(IIM-ILD)成人患者,评估1年内用力肺活量(FVC)和弥散功能(DLCO)变化对10年死亡和肺移植的预测价值。多因素分析显示,1年FVC下降≥5%与10年死亡率增加显著相关(HR=2.78,CI 1.27-6.09,p=0.01),而FVC稳定或改善预测更好预后;DLCO下降与生存无关。
要点
- 1年FVC下降≥5%与10年死亡率增加独立相关(HR=2.78)。
- FVC稳定或改善与更好生存相关(HR=0.38),应作为治疗目标。
- DLCO下降与生存无显著关联,FVC是更关键监测指标。
核心结论
- IIM-ILD患者1年内即使轻度FVC下降(≥5%)也预测死亡和肺移植风险增加。
- FVC稳定或改善与更好生存相关,应视为治疗目标。
研究设计与样本
- 回顾性单中心队列研究,纳入149例成人IIM-ILD患者,按自身抗体状态和2017 EULAR/ACR标准分类,ILD由高分辨率胸部CT(HRCT)定义。
- 纳入要求基线及6-18个月随访肺功能测试(PFT),采用Cox回归和Kaplan-Meier分析PFT变化与生存的关系,多变量模型调整年龄、性别、吸烟、基线FVC和PFT timing。
主要发现
- 149例患者平均年龄50.5±12.9岁,63%女性,最常见亚型为抗合成酶综合征(73%)。
- 平均随访6.3年期间,41例(27.5%)死亡,6例(4.0%)接受肺移植。
- 多变量分析中,1年FVC绝对下降≥5%与10年死亡率增加相关(HR=2.78,CI 1.27-6.09,p=0.01),相对下降≥5%亦相关(HR=2.37,CI 1.11-5.05,p=0.025)。
- 更大FVC下降(≥10%/≥15%)与死亡率关联更强,FVC稳定或改善预测更好结局(HR=0.38,CI 0.18-0.82,p=0.01)。
- DLCO下降与生存无关,Kaplan-Meier分析显示FVC下降≥5%者生存更差(p=0.028),生存不因自身抗体亚型或HRCT模式而异。
关键数值与推荐
- IIM-ILD诊断基于2017 EULAR/ACR标准分类及HRCT定义ILD。
- 1年FVC绝对或相对下降≥5%作为预后不良阈值,与10年死亡率增加独立相关。
临床怎么用
- 常规监测FVC有助于IIM-ILD风险分层,FVC下降≥5%应警惕并考虑强化治疗或移植转诊。
- FVC稳定或改善可作为治疗目标,并可作为临床试验终点。
局限性
- 回顾性单中心设计可能限制普遍性。
- 样本量较小(149例),事件数有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prognostic value of pulmonary function test (PFT) trends in idiopathic inflammatory myopathy-related interstitial lung disease (IIM-ILD) remains unclear. We evaluated whether one-year changes in forced vital capacity (FVC) and diffusing capacity (DLCO) predict 10-year mortality and lung transplantation. METHODS: In a retrospective, single-center cohort of adults with IIM-ILD classified by autoantibody status and 2017 EULAR/ACR criteria, ILD was defined by high-resolution chest CT (HRCT). Inclusion required baseline and follow-up PFTs 6-18 months apart. Cox regression and Kaplan-Meier analyses assessed associations between PFT changes and survival. Multivariable models adjusted for age, sex, smoking, baseline FVC, and PFT timing. RESULTS: The most common IIM subset among 149 patients (mean age 50.5 ± 12.9 years, 63 % female) was anti-synthetase syndrome (73 %). Over mean 6.3-year follow-up, 41 (27.5 %) died and 6 (4.0 %) underwent transplantation. In multivariate analyses, absolute and relative FVC declines of ≥5% over one year were significantly associated with increased 10-year mortality (HR=2.78, CI 1.27-6.09, p = 0.01 and HR=2.37, CI 1.11-5.05, p = 0.025) . Larger FVC declines (≥10%/≥15 %) showed stronger mortality associations, whereas stable or improved FVC predicted better outcomes (HR=0.38, CI 0.18-0.82, p = 0.01). DLCO decline was not associated with survival. Kaplan-Meier analysis demonstrated worse survival with FVC decline≥5 % (p = 0.028). Survival did not differ by autoantibody subtype or HRCT pattern. CONCLUSION: Even modest FVC decline (≥5 %) over one year predicts mortality and transplant in IIM-ILD, while stabilization or improvement in FVC associates with improved survival and should be considered therapeutic goals. Routine FVC monitoring may support risk stratification, guide transplant referral, and serve as a trial endpoint.
引用
- Keret S, Laverde SM, Silva RL, et al. Prognostic significance of 1-year pulmonary function changes in inflammatory myopathy-related interstitial lung disease. Semin Arthritis Rheum. 2026. PMID: 41903313. doi:10.1016/j.semarthrit.2026.152957
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。